Corbus Pharmaceuticals Holdings (LTS:0SZI) Accounts Payable: $0.44 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0SZI Corbus Pharmaceuticals Holdings Inc LTS:0SZI
37 GF Score
Price $8.94
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings Accounts Payable?

Corbus Pharmaceuticals Holdings LTS:0SZI -0.45% 37 Accounts Payable is $0.44 Mil as of Mar. 2026. GuruFocus rates LTS:0SZI with a GF Score™ of 37/100 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Corbus Pharmaceuticals Holdings's Accounts Payable for the quarter that ended in Mar. 2026 was $0.44 Mil.

Corbus Pharmaceuticals Holdings's quarterly Accounts Payable declined from Sep. 2025 ($2.74 Mil) to Dec. 2025 ($2.22 Mil) and declined from Dec. 2025 ($2.22 Mil) to Mar. 2026 ($0.44 Mil).

Corbus Pharmaceuticals Holdings's annual Accounts Payable increased from Dec. 2023 ($3.18 Mil) to Dec. 2024 ($4.79 Mil) but then declined from Dec. 2024 ($4.79 Mil) to Dec. 2025 ($2.22 Mil).

Corbus Pharmaceuticals Holdings Accounts Payable Related Terms

Corbus Pharmaceuticals Holdings Accounts Payable Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings Accounts Payable Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.78 2.17 3.18 4.79 2.22

Corbus Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.07 3.99 2.74 2.22 0.44
LTS:0SZI
37GF Score
Corbus Pharmaceuticals Holdings Inc LTS:0SZI
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.44 Mil mean?
Corbus Pharmaceuticals Holdings (LTS:0SZI) has a Accounts Payable of $0.44 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Corbus Pharmaceuticals Holdings and its competitors.
Is Corbus Pharmaceuticals Holdings' Accounts Payable too high?
Corbus Pharmaceuticals Holdings' current Accounts Payable is $0.44 Mil. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' Accounts Payable compare to PRQR and NRXP?
Corbus Pharmaceuticals Holdings' Accounts Payable of $0.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Corbus Pharmaceuticals Holdings and its competitors. Corbus Pharmaceuticals Holdings's current Accounts Payable is $0.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings (LTS:0SZI) is currently considered Significantly Overvalued. The current Accounts Payable is $0.44 Mil. Corbus Pharmaceuticals Holdings' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (LTS:0SZI), the current Accounts Payable is $0.44 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA3371:Germany
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
37GF Score

Get the complete analysis for LTS:0SZI

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.94
Price